Aerie Pharmaceuticals Inc (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with …
Canaccord Genuity analyst Corey Davis came out with a favorable report on Aerie Pharmaceuticals Inc (NASDAQ:AERI) after the FDA allowed ROCKET 2’s primary endpoint …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 50% on the news that the FDA has agreed to the company’s proposed change in the primary …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) has created a lot of buzz this morning as shares jumped 56% in pre-market trading following news that the …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 56% to $20.75 in pre-market trading after the FDA agreed to allow Aerie to change the …
RBC Capital analyst Adnan Butt weighed in with some commentary on Aerie Pharmaceuticals Inc (NASDAQ:AERI) following an FDA agreement that the company may change the primary endpoint …
In a research report released April 30, Brean Capital analyst Difei Yang reiterated a Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) with a $24 price …
Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares plunged nearly 64% today after the company reported disappointing efficacy results from its first Phase 3 trial for Rhopressa, the company’s lead glaucoma …
In a research report issued Friday, Brean Capital analyst Difei Yang reiterated a Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI), and reduced the price target …